Recently, Araki et al. [14] reported that baseline ALC at a cutoff value of 1500/μl is a predictor for PFS in HER2-positive advanced breast cancer treated with pertuzumab and trastuzumab, irrespective of combination chemotherapy regimens including eribulin. This evidence concerns the gene ERBB2 and breast cancer.